Condition
Chronic Myeloid Leukemia
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 5 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
5 shownCollecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer DetectionNCT05334069 · 2022-08-18
RECRUITINGThe Registry of Oncology Outcomes Associated With Testing and TreatmentNCT04028479 · 2021-05-05
COMPLETEDConsolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid LeukemiaNCT04043676 · 2019-04-30
UNKNOWNPulmonary Vasculopathy Under Second-line Therapy of Chronic Myeloid LeukemiaNCT01805843 · 2012-07-01
COMPLETEDStudy of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALLNCT00349518 · 2006-12-01
WITHDRAWNCommon interventions
Leading sponsors
Trial status mix
COMPLETED2
RECRUITING1
UNKNOWN1
WITHDRAWN1
Phase mix
PHASE22
PHASE31
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.